Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewNeuroscience Open Access | 10.1172/jci.insight.135391

Reactive astrocyte-driven epileptogenesis is induced by microglia initially activated following status epilepticus

Fumikazu Sano,1 Eiji Shigetomi,1 Youichi Shinozaki,1 Haruka Tsuzukiyama,1 Kozo Saito,1 Katsuhiko Mikoshiba,2 Hiroshi Horiuchi,3 Dennis Lawrence Cheung,3 Junichi Nabekura,3 Kanji Sugita,4 Masao Aihara,4 and Schuichi Koizumi1

1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan

4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Find articles by Sano, F. in: PubMed | Google Scholar

1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan

4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Find articles by Shigetomi, E. in: PubMed | Google Scholar |

1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan

4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Find articles by Shinozaki, Y. in: PubMed | Google Scholar |

1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan

4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Find articles by Tsuzukiyama, H. in: PubMed | Google Scholar

1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan

4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Find articles by Saito, K. in: PubMed | Google Scholar

1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan

4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Find articles by Mikoshiba, K. in: PubMed | Google Scholar

1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan

4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Find articles by Horiuchi, H. in: PubMed | Google Scholar

1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan

4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Find articles by Cheung, D. in: PubMed | Google Scholar |

1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan

4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Find articles by Nabekura, J. in: PubMed | Google Scholar

1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan

4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Find articles by Sugita, K. in: PubMed | Google Scholar

1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan

4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Find articles by Aihara, M. in: PubMed | Google Scholar

1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan

4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Find articles by Koizumi, S. in: PubMed | Google Scholar |

Published April 8, 2021 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.135391.
Copyright © 2021, Sano et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published April 8, 2021 - Version history
View PDF
Abstract

Extensive activation of glial cells during a latent period has been well documented in various animal models of epilepsy. However, it remains unclear whether activated glial cells contribute to epileptogenesis; i.e., the chronically persistent process leading to epilepsy. Particularly, it is not clear whether inter-glial communication between different types of glial cells contributes to epileptogenesis, as past literature mainly focused on one type of glial cell. Here, we show that temporally distinct activation profiles of microglia and astrocytes collaboratively contribute to epileptogenesis in a drug-induced status epilepticus model. We found that reactive microglia appeared first, followed by reactive astrocytes and increased susceptibility to seizures. Reactive astrocytes exhibited larger Ca2+ signals mediated by IP3R2, whereas deletion of this type of Ca2+ signaling reduced seizure susceptibility after status epilepticus. Immediate, but not late, pharmacological inhibition of microglial activation prevented subsequent reactive astrocytes, aberrant astrocyte Ca2+ signaling, and the enhanced seizure susceptibility. These findings indicate that the sequential activation of glial cells constitutes a cause of epileptogenesis after status epilepticus. Thus, our findings suggest that the therapeutic target to prevent epilepsy after status epilepticus should be shifted from microglia (early phase) to astrocytes (late phase).

Graphical Abstract
graphical abstract
Supplemental material

View

View S1 Movie

View S2 Movie

View S3 Movie

View S4 Movie

View S5 Movie

View S6 Movie

View S7 Movie

Version history
  • Version 1 (April 8, 2021): In-Press Preview
  • Version 2 (May 10, 2021): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts